These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30382319)

  • 1. Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation.
    Hiligsmann M; Reginster JY; Tosteson ANA; Bukata SV; Saag KG; Gold DT; Halbout P; Jiwa F; Lewiecki EM; Pinto D; Adachi JD; Al-Daghri N; Bruyère O; Chandran M; Cooper C; Harvey NC; Einhorn TA; Kanis JA; Kendler DL; Messina OD; Rizzoli R; Si L; Silverman S
    Osteoporos Int; 2019 Jan; 30(1):45-57. PubMed ID: 30382319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsimulation model for the health economic evaluation of osteoporosis interventions: study protocol.
    Si L; Eisman JA; Winzenberg T; Sanders KM; Center JR; Nguyen TV; Palmer AJ
    BMJ Open; 2019 Feb; 9(2):e028365. PubMed ID: 30782956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
    Hiligsmann M; Cooper C; Guillemin F; Hochberg MC; Tugwell P; Arden N; Berenbaum F; Boers M; Boonen A; Branco JC; Maria-Luisa B; Bruyère O; Gasparik A; Kanis JA; Kvien TK; Martel-Pelletier J; Pelletier JP; Pinedo-Villanueva R; Pinto D; Reiter-Niesert S; Rizzoli R; Rovati LC; Severens JL; Silverman S; Reginster JY
    Semin Arthritis Rheum; 2014 Dec; 44(3):271-82. PubMed ID: 25086470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis.
    Li N; Cornelissen D; Silverman S; Pinto D; Si L; Kremer I; Bours S; de Bot R; Boonen A; Evers S; van den Bergh J; Reginster JY; Hiligsmann M
    Pharmacoeconomics; 2021 Feb; 39(2):181-209. PubMed ID: 33026634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF).
    Hiligsmann M; Cornelissen D; Vrijens B; Abrahamsen B; Al-Daghri N; Biver E; Brandi ML; Bruyère O; Burlet N; Cooper C; Cortet B; Dennison E; Diez-Perez A; Gasparik A; Grosso A; Hadji P; Halbout P; Kanis JA; Kaufman JM; Laslop A; Maggi S; Rizzoli R; Thomas T; Tuzun S; Vlaskovska M; Reginster JY
    Osteoporos Int; 2019 Nov; 30(11):2155-2165. PubMed ID: 31388696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging.
    Shevroja E; Reginster JY; Lamy O; Al-Daghri N; Chandran M; Demoux-Baiada AL; Kohlmeier L; Lecart MP; Messina D; Camargos BM; Payer J; Tuzun S; Veronese N; Cooper C; McCloskey EV; Harvey NC
    Osteoporos Int; 2023 Sep; 34(9):1501-1529. PubMed ID: 37393412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review.
    Li N; Beaudart C; Cauley JA; Ing SW; Lane NE; Reginster JY; Silverman S; Singer AJ; Hiligsmann M
    Pharmacoeconomics; 2023 Apr; 41(4):363-391. PubMed ID: 36738425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
    Honvo G; Bannuru RR; Bruyère O; Rannou F; Herrero-Beaumont G; Uebelhart D; Cooper C; Arden N; Conaghan PG; Reginster JY; Thomas T; McAlindon T
    Drugs Aging; 2019 Apr; 36(Suppl 1):145-159. PubMed ID: 31073927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
    Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
    Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
    Reginster JL; Arden NK; Haugen IK; Rannou F; Cavalier E; Bruyère O; Branco J; Chapurlat R; Collaud Basset S; Al-Daghri NM; Dennison EM; Herrero-Beaumont G; Laslop A; Leeb BF; Maggi S; Mkinsi O; Povzun AS; Prieto-Alhambra D; Thomas T; Uebelhart D; Veronese N; Cooper C
    Semin Arthritis Rheum; 2018 Aug; 48(1):1-8. PubMed ID: 29287769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
    Moon RJ; Reginster JY; Al-Daghri NM; Thiyagarajan JA; Beaudart C; Bruyère O; Burlet N; Chandran M; da Silva MC; Conaghan PG; Dere WH; Diez-Perez A; Hadji P; Halbout P; Hiligsmann M; Kanis JA; McCloskey EV; Ormarsdottir S; Prieto-Alhambra D; Radermecker RP; Rizzoli R; Al-Saleh Y; Silverman SL; Simon LS; Thomasius F; van Staa T; Laslop A; Cooper C; Harvey NC
    Osteoporos Int; 2023 Aug; 34(8):1283-1299. PubMed ID: 37351614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advocating uniformity in spine surgery: a practical disease-specific guideline for trial-based economic evaluations.
    Schuermans VNE; Droeghaag R; Hermans SMM; Smeets AYJM; Caelers IJMH; Hiligsmann M; van Hemert WLW; Evers S; van Santbrink H;
    BMJ Open; 2023 Jul; 13(7):e073535. PubMed ID: 37433725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model.
    Zethraeus N; Borgström F; Ström O; Kanis JA; Jönsson B
    Osteoporos Int; 2007 Jan; 18(1):9-23. PubMed ID: 17093892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture.
    Majumdar SR; Lier DA; Rowe BH; Russell AS; McAlister FA; Maksymowych WP; Hanley DA; Morrish DW; Johnson JA
    Osteoporos Int; 2011 Jun; 22(6):1799-808. PubMed ID: 20878389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based recommendations for economic evaluations in spine surgery: study protocol for a Delphi consensus.
    Droeghaag R; Schuermans VNE; Hermans SMM; Smeets AYJM; Caelers IJMH; Hiligsmann M; van Hemert WLW; Evers S; van Santbrink H
    BMJ Open; 2021 Dec; 11(12):e052988. PubMed ID: 34949622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impact and cost-effectiveness of fracture liaison services: a systematic review of the literature.
    Wu CH; Kao IJ; Hung WC; Lin SC; Liu HC; Hsieh MH; Bagga S; Achra M; Cheng TT; Yang RS
    Osteoporos Int; 2018 Jun; 29(6):1227-1242. PubMed ID: 29460102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom.
    Svedbom A; Hadji P; Hernlund E; Thoren R; McCloskey E; Stad R; Stollenwerk B
    Osteoporos Int; 2019 Sep; 30(9):1745-1754. PubMed ID: 31270592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A health economic simulation model for the clinical management of osteoporosis.
    Jonsson E; Hansson-Hedblom A; Ljunggren Ö; Åkesson K; Spångeus A; Kanis JA; Borgström F
    Osteoporos Int; 2018 Mar; 29(3):545-555. PubMed ID: 29196775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.